[NMDA-dependent component in effects of pyracetam and GBC-111, the new peptide with the nootropic activity, on EEG in the cerebral cortex and hippocampus from non-narcotized rats].
Kovalev
G I
GI
Vorob'ev
V V
VV
Akhmetova
E P
EP
D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects* / Q000502:physiology; D004151:Dipeptides / Q000494:pharmacology*; D004569:Electroencephalography; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects* / Q000502:physiology; D018697:Nootropic Agents / Q000494:pharmacology*; D010889:Piracetam / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology*
D004151:Dipeptides; D018691:Excitatory Amino Acid Antagonists; D018697:Nootropic Agents; D016194:Receptors, N-Methyl-D-Aspartate; C103871:ethyl phenylacetyl-Pro-Gly; D010889:Piracetam